From September 14 to October 18, WeHealth™ Digital Medicine is participating in the virtual edition of the ESMO (European Society for Medical Oncology) congress. With more than 25,000 members representing oncology professionals from over 160 countries worldwide, ESMO is the society of reference for oncology education and information.
On WeHealth™ Digital Medicine virtual booth, healthcare professionals will be able to discover how the latest innovations in digital health can support the improvement of their practices and their potential clinical impact. They will discover oncology solutions designed to simplify their daily life, improve patient follow-up, and improve clinical decisions through genomic markers analysis and through solid tumor size follow-up.
Toward personalized medicine
The challenge of WeHealth™ Digital Medicine: to foster personalized medicine. Its strategy: to process patients own molecular profile data performing multi-omic analysis. The ultimate patient benefit targeted: data intelligence to go further in precision medicine. How? By using algorithms to analyze genetic information and compare it with a large and various intelligent database.
On the booth, the following solutions will be presented to you:
BIONOV™: a clinical decision support software as a service intended to provide oncologists with cancer treatment options primarily based on molecular profile inputs and disease histology for their cancer patients (co-developed with Curematch®).
ON’COHUB™: a clinical decision support software (as a service or on premise) designed to facilitate the follow up of solid tumors size evolution in cancer patients (co-developed with Deeplink Medical™)